Search
Massachusetts Paid Clinical Trials
A listing of 3204 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2269 - 2280 of 3204
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Evaluating Treatment of ADHD in Children with Down Syndrome
Recruiting
Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD.
The investigators propose the first randomized... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/14/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Down Syndrome, ADHD
Effects of Transcranial Pulse Stimulation in Parkinson's Disease
Recruiting
The investigators are studying if Transcranial Pulse Stimulation (TPS) can improve various symptoms, including movement problems, thinking abilities, mood, fatigue, freezing while walking, voice quality, and issues with smell and taste. Previous research suggests TPS might help in Alzheimer's disease and could be helpful for Parkinson's as well. Investigators will check if TPS is safe, practical, and if it makes a noticeable difference in these symptoms compared to before the treatment.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
01/13/2025
Locations: Spaulding Rehabilitation Hospital, Cambridge, Massachusetts
Conditions: Parkinson
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
Recruiting
Obesity has become an important public health issue that leads to insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular diseases. Although weight loss with calorie restriction and increased physical activity improve these complications, many people fail these lifestyle interventions. Therefore, pharmacologic agents have been used for weight management in addition to lifestyle interventions. In the past few years, one of the widely used pharmacologic agents for weight manag... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Overweight and Obesity
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Recruiting
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Recruiting
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma.
The names of the study drugs involved in this study are:
* Glofitamab (a type of immunotherapy)
* Obinutuzumab (a type of immunotherapy)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Recruiting
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
Recruiting
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.
Gender:
ALL
Ages:
Between 0 years and 1 year
Trial Updated:
01/10/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Recruiting
Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
01/10/2025
Locations: Boston University School of Medicine, Boston, Massachusetts
Conditions: Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients with Hutchinson-Gilford Progeria Syndrome (HGPS)
Recruiting
Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
01/09/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hutchinson-Gilford Progeria Syndrome
ZN-c3 + Gemcitabine in Pancreatic Cancer
Recruiting
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer.
The names of the study drugs involved in this study are:
* ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)
* Gemcitabine (a nucleoside metabolic inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Recruiting
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
01/09/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sickle Cell Disease
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Recruiting
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/09/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Carcinoma, Non-Small-Cell Lung